Driven by Al and collapsing research costs, there will be more scientific breakthroughs in the next few years than in the preceding decades
https://t.co/BYQEOZLmgS
On Tuesday I spoke at Apex Zurich about longevity as an investment theme, together with Greg Bailey , @marcpbernegger and Ole Mensching.
My view is simple: longevity will be one of the largest investment themes of the coming decades. For years it was treated as a niche for biohackers and billionaires. That is changing fast.
With GLP-1s we already have the first #longevity drug on the market, even if it was never approved as one. Developed for diabetes and obesity, the data now show much more. In the SELECT trial, semaglutide cut major cardiovascular events by 20% in overweight patients without diabetes. The FLOW trial showed a 24% lower risk of serious kidney outcomes. Studies on addiction, liver disease and inflammation point in the same direction. One molecule, many diseases of ageing.
What I find most interesting is the convergence of consumer health, prevention and pharma. These used to be separate worlds. GLP-1s brought them together: patients paying out of pocket, and using the drug well beyond its original label. @EliLillyandCo and @novonordisk now sell directly to consumers.
The largest pharma companies are now focusing on drugs with the largest TAM, where healthy people, not just sick patients, become the market and where off-label adoption drives demand. That is exactly what longevity is. The market for GLP-1s alone is expected to pass $100bn per year.
GLP-1s are the beginning, not the end. The next wave will come from cellular rejuvenation, organ preservation, AI-driven drug discovery and much better diagnostics.
Thank you to the @ApexGlobalGroup team for a great evening and to Greg, Marc and Ole for an excellent discussion.
Two masterclasses are kicking off!
📍 Hal Finney Room: @marcpbernegger explores why early Bitcoiners are drawn to longevity.
📍 UTXO Room: @BTCSessions and @theBTCmentor share lessons from the Coldcard hack.
Happening now at Plan ₿ Forum 2026!
𝐁𝐢𝐭𝐜𝐨𝐢𝐧 𝐦𝐞𝐞𝐭𝐬 𝐋𝐨𝐧𝐠𝐞𝐯𝐢𝐭𝐲: 𝐖𝐡𝐚𝐭 𝐝𝐨 𝐭𝐡𝐞𝐬𝐞 𝐭𝐰𝐨 𝐰𝐨𝐫𝐥𝐝𝐬 𝐡𝐚𝐯𝐞 𝐢𝐧 𝐜𝐨𝐦𝐦𝐨𝐧? 🧬 ₿
At this year’s Lugano's Plan ₿ Forum, Maximon’s and Longevity Investors Co-Founder Marc P. Bernegger explore an interesting connection
Im Inneren der exklusivsten Longevity-Konferenz: In Gstaad versammelte sich eine handverlesene Milliardärsgilde mit einigen der unkonventionellsten Köpfe der Longevity-Forschung. Von Covid und Blutreinigung über Gen-Editing bis hin zu We... https://t.co/F2CEx58Rip
🚨 Applications for #cfcstmoritz 2027 are open. Suvretta House, January 13th to 15th, with the Pre-Opening from the 11th.
Our board committee reviews every application in the order it arrives, and the first 48 hours carry our early bird rate. 👉 https://t.co/mV59MKMOjh
At LIC 2026, investors, scientists and founders examined what survives the journey from longevity hypothesis to human evidence.
https://t.co/9gxadMpLpX
#longevity#LIC2026#investors#scientists#evidence
@Scaramucci returns to CfC St. Moritz in January. Few people in digital assets have moved through as many different corners of the financial and political world, from Wall Street and alternative investments to the White House and the crypto industry.
That wealth of experience makes for a perspective we look forward to having back in the room.
Refreshing to meet Marc P. Bernegger @marcpbernegger , Co-Founder and Chairman of Longevity Investors @Longevity_Inv and Maximon @maximon_ag, The Longevity Company Builder, at CV Summit 2026 in Switzerland. We discussed shared opportunities for the @DMCCLongevity and Dubai’s prospects following the latest landmark milestones from the Dubai Longevity Authority.
Switzerland demonstrates what becomes possible when science, capital, and entrepreneurship reinforce each other. It has one of the highest life expectancies in the world. Its chemical, pharmaceutical, and life sciences industries account for CHF 152.1 billion, or 53%, of Swiss exports, and its biotech sector raised CHF 2.6 billion in 2025 while investing CHF 2.5 billion in R&D. Dubai is now establishing the framework to transform that same ambition into a thriving commercial industry.
Established by @HHShkMohd in June, the Dubai Longevity Authority serves as a dedicated regulator for longevity, wellness, and advanced health across the entire value chain. On 27 Sept, @HamdanMohammed approved its strategy and budget, targeting approximately 31% annual growth and over AED 35 billion in economic contribution over the next decade.
Spanning R&D, clinical trials, manufacturing, and commercialisation, the Authority’s mandate includes a supervised Minimum Viable Product programme designed to help innovators test and scale. Its focus is healthspan, the number of years people live in good health, and its work supports Dubai Economic Agenda ‘D33’ and Social Agenda 33.
This creates three immediate avenues for collaboration.
Since 2020, the Longevity Investors Conference @Longevity_Inv has united investors, scientists, and founders from Gstaad to Davos, providing a network that can connect serious capital with emerging @dmccfinx opportunities as Dubai moves into implementation.
@maximon_ag builds science-based longevity ventures, supported by a Longevity Co-Investment Fund with a CHF 100 million target, and Dubai’s combination of a science-driven regulator and an established business ecosystem offers a natural base for regional expansion.
Maximon’s AYUN clinic in Zurich pairs physician-led diagnostics with personalised preventive care, and its plans for the Middle East create clear scope for exchange with our clinical community.
The @DMCCLongevity already brings together nearly 400 member companies, 108 of them @DHA_Dubai approved, including The Brain & Performance Centre, a @DP_World company.
With the regulator in place and the business community established, the next step is connecting the right science and capital to them. Switzerland and Dubai bring distinct, complementary strengths to the same objective: longer lives, lived in better health.
🎙 @cz_binance, entrepreneur & founder of @binance, returns to the #Engadin. CZ last joined us in 2023, and since then the industry matured greatly.
Looking forward to hearing his insights and opinions from his wider set of experience with @giggleacademy, @yzilabs and more.
That's a wrap on the 7th Longevity Investors Conference.
Thank you to every speaker, partner, start-up and investor who made it what it was. See you at the next one.
#LongevityInvestors#LIC2026
Low time preference.
Taken very, very literally. 😉
Bitcoin meets Longevity: Why many early Bitcoiners are drawn to life extension
In this masterclass, @marcpbernegger explores why Bitcoiners and longevity enthusiasts seem to keep finding each other.
Long-term thinking say hello to really long-term thinking...?
Join us for it at Plan ₿ Forum 2026.
📅 Mark the date: Applications for CfC St. Moritz 2027 will open on October 14th. Tickets are not publicly available 👉 our board committee reviews every application and selects the final participants. The current admission rate at #cfcstmoritz is 12%.
𝐋𝐨𝐧𝐠𝐞𝐯𝐢𝐭𝐲 𝐢�� 𝐬𝐭𝐚𝐫𝐭𝐢𝐧𝐠 𝐭𝐨 𝐥𝐨𝐨𝐤 𝐚 𝐥𝐨𝐭 𝐥𝐢𝐤𝐞 𝐛𝐥𝐨𝐜𝐤𝐜𝐡𝐚𝐢𝐧 𝐝𝐢𝐝 𝐛𝐞𝐟𝐨𝐫𝐞 𝐢𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐢𝐨𝐧𝐚𝐥 𝐜𝐚𝐩𝐢𝐭𝐚𝐥 𝐚𝐫𝐫𝐢𝐯𝐞𝐝.
Marc P. Bernegger in a conversation with https://t.co/2Hsxwyxgni
@Longevity_Inv is being framed as a $600 billion investment opportunity, but is the money there yet?
@marcpbernegger, Co-Founder & Chairman of @Longevity_Inv, tells @RPether the sector still needs "the GDP moment", a handful of scaled, listed companies to pull in institutional capital.